Guochuang Tongqiao: Net profit in 2025 increases by 143.7% year-on-year to 244 million yuan, with rapid growth in sales of neurovascular intervention products

Recently, GuiChuang TongQiao released its annual performance report for the fiscal year ending December 31, 2025. The company achieved revenue of 1.057 billion yuan, a year-on-year increase of 35.1%; gross profit was 763 million yuan, with a gross profit margin of 72.1%. Net profit for the year was 244 million yuan, a significant increase of 143.7% year-on-year. Non-IFRS adjusted net profit for the year was 273 million yuan, up 120.2%.

The significant growth in revenue mainly benefited from the rapid increase in sales of neurovascular and peripheral vascular interventional devices, which grew by 28.0% and 50.3%, respectively. Neurovascular interventional products accounted for 64.1% of total revenue, while peripheral vascular interventional products accounted for 35.9%. During the reporting period, the company continued to improve medical services, with smooth progress in product research, development, and commercialization.

Management mentioned that the growth in neurovascular interventional product sales was mainly due to the promotion of new products and substantial increases in revenue from key mature products. The growth of peripheral vascular interventional products was driven by expanded market access and strengthened sales networks. Overall, the company’s neurovascular and peripheral vascular interventional businesses achieved significant growth during the reporting period. Moving forward, the company will continue to focus on product innovation and market expansion to further increase market share and profitability.

(GuiChuang TongQiao Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical